Skip to content

A comparison of efficacy between combination use of methylergonovine intravenous slowly push plus oxytocin continuous infusion and carbetocin intravenous slowly push for prevent postpartum hemorrhage in cesarean section

A comparison of efficacy between combination use of methylergonovine intravenous slowly push plus oxytocin continuous infusion and carbetocin intravenous slowly push for prevent postpartum hemorrhage in cesarean section

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200401001
Enrollment
50
Registered
2020-04-01
Start date
2020-03-25
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postpartum hemorrhage &#44

Interventions

after delivered fetus,after delivered fetus
Active Comparator Drug,Experimental Drug
oxytocin infusion plus methylergonovine slowly push,cabetocin slowly push

Sponsors

None
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: singleton pregnancy gestational age between 34-42 weeks

Exclusion criteria

Exclusion criteria: pregnancy with - eclampsia or preeclampsia - hypertension - coagulation disorder - anemia - polycythemia - blood transfusion - ischemic heart disease - cerebrovascular disease - peripheral vascular disease - asthma - placenta previa - placental abruption - allergy to carbetocin , oxytocin or methylergonovine - cannot speak thai language - fetal distress

Design outcomes

Primary

MeasureTime frame
reduced blood loss after cesareansection 4 hours two sample t test

Secondary

MeasureTime frame
side effect from drug intra-operative and post-operative Chi-square test

Countries

Thailand

Contacts

Public ContactThanawin Tattamanas

Department of Obstetrics &Gynecology , Phramongkutkloa hospital

migwormmy36@gmail.com0868882545

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026